161 related articles for article (PubMed ID: 37195667)
21. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
[TBL] [Abstract][Full Text] [Related]
22. S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
Wang X; Ge X; Wang X; Zhang W; Zhou H; Lin Y; Qie S; Hu M; Wang W; Liu K; Pang Q; Li M; Chen J; Liu M; Zhang K; Li L; Shi Y; Deng W; Li C; Ni W; Chang X; Han W; Deng L; Wang W; Liang J; Bi N; Zhang T; Liu W; Wang J; Zhai Y; Feng Q; Chen D; Zhou Z; Zhao Y; Sun X; Xiao Z
Front Oncol; 2020; 10():1499. PubMed ID: 32983991
[No Abstract] [Full Text] [Related]
23. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
24. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
[TBL] [Abstract][Full Text] [Related]
25. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
26. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
29. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
30. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
31. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
Shinoda M; Ando N; Kato K; Ishikura S; Kato H; Tsubosa Y; Minashi K; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Nakamura K; Fukuda H;
Cancer Sci; 2015 Apr; 106(4):407-12. PubMed ID: 25640628
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
33. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
35. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
[TBL] [Abstract][Full Text] [Related]
36. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Kong FM; Ten Haken RK; Schipper M; Frey KA; Hayman J; Gross M; Ramnath N; Hassan KA; Matuszak M; Ritter T; Bi N; Wang W; Orringer M; Cease KB; Lawrence TS; Kalemkerian GP
JAMA Oncol; 2017 Oct; 3(10):1358-1365. PubMed ID: 28570742
[TBL] [Abstract][Full Text] [Related]
37. [A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].
Xu YJ; Zhu WG; Liao ZX; Kong Y; Wang WW; Li JC; Huang R; He H; Yang XM; Liu LP; Sun ZW; He HJ; Bao Y; Zeng M; Pu J; Hu WY; Ma J; Jiang H; Liu ZG; Zhuang TT; Tan BX; Du XH; Qiu GQ; Zhou X; Ji YL; Hu X; Wang J; Ma HL; Zheng X; Huang J; Liu AW; Liang XD; Tao H; Zhou JY; Liu Y; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(23):1783-1788. PubMed ID: 32536123
[No Abstract] [Full Text] [Related]
38. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
Chen H; Zhou L; Yang Y; Yang L; Chen L
Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
[TBL] [Abstract][Full Text] [Related]
39. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
40. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
